The countdown to Siemens Healthineers’ second-quarter results on May 7 has taken on an unusually high-stakes character, with the stock languishing near its 52-week low and a series of structural challenges weighing on investor sentiment. At €36.32, the shares have shed roughly a fifth of their value since the start of the year, leaving them more than 17% below the 200-day moving average of around €44. The relative strength index, hovering near 35, points to oversold territory — yet a meaningful bounce has so far failed to materialize.
A Dual Drag: Tariffs and Currency Headwinds
Behind the price weakness lies a sobering operational picture. While first-quarter revenues edged up 3.8%, adjusted earnings per share slipped to €0.49 — a 3% decline from a year earlier. The diagnostics division contracted by 3%, hampered by China’s anti-corruption campaign, which has centralized procurement processes and disrupted sales cycles.
More ominously, fresh US tariffs are expected to weigh on adjusted EBIT by roughly €400 million this year, with negative currency effects adding another €200 million to €250 million. Despite these headwinds, management has held firm on its full-year guidance: comparable revenue growth of 5% to 6%, and adjusted EPS in a range of €2.20 to €2.40.
The Spin-Off Question That Won’t Go Away
What preoccupies many investors even more than quarterly earnings, however, is the impending separation from parent Siemens AG. Once Siemens distributes its 30% stake to its own shareholders — a move that could trigger a formal vote as early as 2027 — the corporate guarantee backing up to €13.9 billion in Healthineers debt will vanish. The company will then need to refinance that borrowing independently, a process that raises legitimate questions about its future capital structure.
Concrete details on the spin-off timeline were expected by early in the second calendar quarter of 2026. That deadline has now passed without clarity, leaving the market to speculate about delays. RBC, which maintains an “Outperform” rating and a €55 price target — implying more than 50% upside — acknowledges that a protracted separation process could disappoint shareholders.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
AI Ambitions and Clinical Progress
Away from the balance sheet concerns, Siemens Healthineers has been making strategic moves to bolster its long-term growth narrative. At the DMEA conference in Berlin, the company unveiled its “Patient Twinning” technology, which creates digital replicas of patients for more precise diagnostics. Martin Stumpe, a former Google and NASA scientist, has been appointed chief technology officer to spearhead the AI push. Five new partners have also joined the Teamplay Digital Health Platform Connect, extending its reach into wound management and AI-driven clinical decision support.
On the clinical front, the FAST-III study confirmed the safety and efficacy of a less invasive method for guiding coronary revascularization, positioning the Advanced Therapies segment as a credible alternative to pressure-wire-based approaches.
What the Market Will Watch on May 7
When Siemens Healthineers reports second-quarter numbers on May 7, the focus will extend well beyond the usual metrics. Analysts will scrutinize the adjusted EBIT margin and revenue trends in Imaging and Varian, looking for signs that the core business is stabilizing. But the real test may be whether management can deliver convincing clarity on the spin-off timeline — and whether the €400 million tariff hit is fully baked into expectations.
RBC’s €55 target assumes the earnings report restores confidence in the growth story. With the stock trading at roughly half that level, the bar for a positive surprise is high. For now, Siemens Healthineers finds itself caught between a promising technological future and a present weighed down by tariffs, currency headwinds, and an unresolved corporate divorce.
Ad
Siemens Healthineers Stock: Buy or Sell?! New Siemens Healthineers Analysis from April 23 delivers the answer:
The latest Siemens Healthineers figures speak for themselves: Urgent action needed for Siemens Healthineers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 23.
Siemens Healthineers: Buy or sell? Read more here...
